Statement by the board of directors of Elos Medtech regarding the public offer from TA Associates
The board of directors unanimously recommends the shareholders to accept the offer from TA Associates. This statement is made by the board of directors of Elos Medtech AB (publ) (”Elos Medtech”) pursuant to Rule II.19 of the Nasdaq Stockholm Takeover Rules (the ”Takeover Rules”). The Offer On 11 June 2021, TA XIII[1], through EM Intressenter AB, announced a public offer of SEK 215 per share to the shareholders in Elos Medtech (the ”Offer”). The Offer values all shares in Elos Medtech at approximately SEK 1,735 million. Shareholders with a total of 21.2 per cent of the shares and